Personalized Medicine in Oncology and the Implication for Clinical Development
The notable success of imatinib for the treatment of chronic myeloid leukemia and trastuzumab for the management of HER2-positive breast cancer patients has generated great enthusiasm for the delivery of more effective and safer treatment to patients based on the genetic anomalies harbored by their cancer. Subsequently, the identification of driver mutations and cancer genome sequencing have facilitated the development of novel targeted anticancer agents. Unfortunately, the attempt to replicate the success of these medications have been far less successful.
In this whitepaper, Dr. Jamal Gasmi, MD, PhD, will address the following:
- Challenges we are facing in the personalized oncology era
- A look at how advances have been made and how clinical development must evolve to better individualize patient care
- The implications of personalized medicine in clinical development
